A photo of James Geller.

James I. Geller, MD


  • Director - Liver, Kidney and Retinoblastoma Programs, Cancer and Blood Diseases Institute
  • Director, Advanced Cancer Therapy Network, Cancer and Blood Disease Institute
  • Director, Pilot Translational Core Grant Program, Center for Clinical and Translational Science and Training
  • Professor, UC Department of Pediatrics

About

Biography

James I. Geller, MD, started in the Division of Oncology at Cincinnati Children's Hospital Medical Center as an assistant professor within the UC Department of Pediatrics in 2004. Currently, he is the medical director of Liver and Renal Tumor Programs and co-director of the Retinoblastoma Program.

His primary academic interest is the development of novel therapy options for infants, children, adolescents and young adults with solid tumors. At the institutional level, he achieves this through direct patient care and by leading our teams in clinical and research efforts in my specialty areas at Cincinnati Children’s Hospital Medical Center. At the national level, he participates as a member of the Children’s Oncology Group (COG) Renal Tumor (RTC), Liver Tumor, Retinoblastoma and Central Nervous System Committees; He functions as vice chair for the RTC and liaison to the COG Developmental Therapeutics Committee (DVL) and Pediatric Preclinical Testing Program as well as chair both the RTC Developmental Therapeutics Working Group and the COG High Risk Renal Tumors Protocols including AREN1721 (focused on immunotherapy and anti-angiogenic therapy for TFE Renal Cell Carcinoma), AREN1921 (focused on relapsed and anaplastic Wilms tumor), and has drafted the next concept for study of epigenetic therapy plus chemotherapy for treatment of rhabdoid tumor. He also serves as co-chair of the COG liver tumor protocol, the Pediatric Hepatic International Tumor Trial (PHITT); AHEP1531.

It is his goal to help facilitate the development of novel therapy for young patients affected with solid tumors. Current areas of expansion include the establishment of the Translational RCC Research Initiatives including a registry for TFE RCC, and development of data harmonization and treatment optimization for relapsed pediatric liver cancers. Integration of cellular and immunotherapy, as well as novel interventional therapeutics, remains a priority.

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Selected

Feasibility of using CT volume as a predictor of specimen weight in a subgroup of patients with low risk Wilms tumors registered on COG Study AREN03B2: implications for central venous catheter placement. Ferrer, FA; Herbst, KW; Fernandez, CV; Khanna, G; Dome, JS; Naranjo, A; Mullen, EA; Geller, JI; Gratias, EJ; Shamberger, R; et al. Journal of Pediatric Urology. 2014; 10:969-973.

Selected

Detection of preoperative wilms tumor rupture with CT: a report from the Children's Oncology Group. Khanna, G; Naranjo, A; Hoffer, F; Mullen, E; Geller, J; Gratias, EJ; Ehrlich, PF; Perlman, EJ; Rosen, N; Grundy, P; et al. Radiology. 2013; 266:610-617.

Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults. Sumazin, P; Peters, TL; Sarabia, SF; Kim, HR; Urbicain, M; Hollingsworth, EF; Alvarez, KR; Perez, CR; Pozza, A; Najaf Panah, MJ; et al. Journal of Hepatology. 2022.

Skeletal muscle mass as a marker to predict outcomes in children and young adults with cancer. McBee, MP; Woodhouse, C; Trout, AT; Geller, JI; Smith, EA; Zhang, B; Towbin, AJ. Abdominal Radiology. 2022; 47:452-459.

Comparison of 0.3-mSv CT to Standard-Dose CT for Detection of Lung Nodules in Children and Young Adults With Cancer. Thapaliya, S; Gilligan, LA; Brady, SL; Anton, CG; Crotty, EJ; Nasser, MP; Geller, JI; Pressey, JG; Zhang, B; Dillman, JR; et al. American Journal of Roentgenology. 2021; 217:1444-1451.

Identification of distinct tumor cell populations and key genetic mechanisms through single cell sequencing in hepatoblastoma. Bondoc, A; Glaser, K; Jin, K; Lake, C; Cairo, S; Geller, J; Tiao, G; Aronow, B. Communications Biology. 2021; 4.

Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models. Johnston, ME; Rivas, MP; Nicolle, D; Gorse, A; Gulati, R; Kumbaji, M; Weirauch, MT; Bondoc, A; Cairo, S; Geller, J; et al. Hepatology. 2021; 74:2201-2215.

Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus Report. Meijer, AJ M; Van Den Heuvel-Eibrink, MM; Brooks, B; Am Zehnhoff-Dinnesen, AG; Knight, KR; Freyer, DR; Chang, KW; Hero, B; Papadakis, V; Frazier, AL; et al. JAMA Oncology. 2021; 7:1550-1558.

Pancreatic Masses in Children and Young Adults: Multimodality Review with Pathologic Correlation. Qiu, L; Trout, AT; Ayyala, RS; Szabo, S; Nathan, JD; Geller, JI; Dillman, JR. Radiographics. 2021; 41:1766-1784.

Denys-Drash Syndrome. Grewal, SS; Towbin, RB; Li, Y; Geller, JI; Towbin, AJ. Applied Radiology. 2021; 50:61-63.

From the Blog


Surgery for a Child with Trisomy 18
Heart and Lung

Surgery for a Child with Trisomy 18

James I. Geller, MD, David S. Cooper, MD, MPH ...3/20/2022

Hepatoblastoma in Kids: Most Frequently Asked Questions
BlogCancer and Blood Diseases

Hepatoblastoma in Kids: Most Frequently Asked Questions

By James Geller, MD3/27/2019

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey